REG - Oxford Biomedica PLC - PDMR Dealings

Oxford BioMedicaAnnouncement

14/11/2023 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231114:nRSN4264Ta&default-theme=true

RNS Number : 4264T  Oxford Biomedica PLC  14 November 2023

 

 

PDMR Dealings

 

Oxford, UK - 14 November 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, today announces that Dr. Michael Hayden, a Non-Executive
Director of the Company has purchased 10,000 ordinary shares of 50p each
("Ordinary Shares") in the Company on 13 November 2023 on the London Stock
Exchange at a price of £1.9281. Following this purchase Dr. Michael Hayden
holds 26,063 shares representing 0.0269% of the Company.

 

The below notifications, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the number of ordinary shares
purchased.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Michael Hayden
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £1.9281   10,000

 e)  Aggregated information

     -Aggregate volume                        10,000

     -Aggregated total

                                              £19,281.00
 f)  Date of the transaction                  2023-11-13
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-Aggregate volume

-Aggregated total

 

 

10,000

 

£19,281.00

f)

Date of the transaction

2023-11-13

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSVLLLSLIV